Toronto-based FSD Pharma Inc. has advanced its exit from cannabis with the recent sale of its former marijuana processing facility in Cobourg, Ont.
Instead, FSD Pharma has renewed its focus as a biotech company, with the goal being to advance “novel drug candidates targeting lucrative areas of unmet medical needs” such as Muscular Sclerosis, depression disorders and inflammatory disorders.
Anthony Durkacz, interim CEO and co-executive chairman of FSD Pharma, suggests the sale puts the company in a good position moving forward. “Combined with our existing cash on hand, we are sufficiently capitalized for operations through 2025, inclusive of budget allocations for planned clinical trials and without having to look to the capital markets for any additional funds,” Durkacz reports.
Noting the company’s vision is to “improve the quality of life of patients,” the website reports FSD Pharma has three drug candidates in different
Read full article on The Growth Op